Bausch + Lomb Corp (BLCO) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate Glaukos’ ability to scale innovative ophthalmic therapies, positioning it as a fast‑growing leader in both glaucoma and corneal‑disease markets while setting the stage for sustained revenue expansion.

Key Takeaways

• Q4 sales $143.1M, 36% YoY growth.
• iDose TR drives $45M Q4, $136M FY sales.
• Epioxa FDA approved, launch covering 50% US population.
• 2026 revenue guidance $600‑620M, >20% YoY growth.
• Operating expenses rise mid‑teens, targeting cash‑flow breakeven.

Pulse Analysis

Glaukos’ fourth‑quarter earnings underscore a rare combination of strong organic growth and strategic product launches. The iDose TR micro‑invasive glaucoma surgery (MIGS) device continued to outpace expectations, delivering $45 million in quarterly sales and $136 million for the year, buoyed by a recent FDA label supplement that permits unlimited readministration. This regulatory win not only expands the therapy’s addressable patient pool but also reinforces Glaukos’ positioning as a pioneer in minimally invasive ocular interventions, a segment that is rapidly gaining traction among ophthalmologists seeking safer, office‑based solutions.

The approval of Epioxa, the first FDA‑cleared topical cross‑linking treatment for keratoconus, adds a transformative corneal‑health offering to Glaukos’ portfolio. By deploying O2n capital systems to sites covering roughly 50% of the U.S. population and securing early payer conversations that reach half of commercially insured lives, the company is laying a robust foundation for rapid market penetration. The pending permanent J‑code, slated for July 2026, will further streamline reimbursement, while co‑pay assistance and specialty pharmacy programs aim to remove financial barriers for patients, accelerating adoption in a historically underserved rare‑disease space.

Looking ahead, Glaukos balances aggressive growth with disciplined capital allocation. Operating expenses are projected to rise in the mid‑teens, yet the firm targets cash‑flow breakeven through operating leverage and continued R&D investment. A deep pipeline—including next‑generation iDose TReX, iStent Infinite, and retinal therapy GOK‑401—promises additional revenue streams and reinforces the company’s long‑term vision of becoming a diversified ophthalmic leader. Investors will watch how effectively Glaukos translates its innovative pipeline into commercial success while navigating competitive pressures in both glaucoma and corneal markets.